
|Articles|October 15, 2006
New Products & Services
Irvine, CA-The Cryocare CN2 System from Endocare, Inc. has received 510K clearance from the FDA. The device uses the freezing capability of nitrogen at the point between gas and liquid-"critical nitrogen"-to destroy cancerous tissue quicker and more cost-effectively than argon can, according to the manufacturer. The speed and precision of this new technology can expedite procedures, Endocare says, because it is easy to use and it delivers a colder, more powerful ice ball at the end of the probes.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
2
Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC
3
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
4
Amanda North, MD, recaps SWIU 2026 session on imposter syndrome
5






